Tuesday, November 5
Shadow

Pharma Giant Gilead Retracts Request FDA Extend Monopoly Status on Experimental Covid-19 Drug

by admin

Pharma Giant Gilead Retracts Request FDA Extend Monopoly Status on Experimental Covid-19 Drug

Pharmaceutical giant Gilead Sciences on Wednesday retracted its effort to score extended monopoly rights and tax breaks on its antiviral drug remdesivir, which scientists are evaluating as a possible treatment in the novel coronavirus pandemic.

Read more…

Go to Source

Related posts:

  1. Coronavirus US live: FDA approves experimental drug remdesivir for emergency use
  2. Eli Lilly’s Covid-19 Antibody Drug Just Received Emergency FDA Clearance
  3. Scientists Say Their Experimental Drug Knocks Out the Flu, in Animal Tests at Least
  4. FDA Shoots Down Plan to Extend Vaccine Supply With Alternate Dosing
  5. Peanut allergy drug approved by the US FDA
Exit mobile version

Terms and Conditions - Privacy Policy